Stockscreener 앱 받기
4.36
18.66%
-1.00
시간 외 거래:
4.34
-0.02
-0.46%
전일 마감가:
$5.36
열려 있는:
$5.25
하루 거래량:
61,321
Relative Volume:
2.44
시가총액:
$112.29M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-27.21%
1개월 성능:
-65.29%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$4.1101
$5.36
1주일 범위
$4.1101
$6.14
52주 변동 폭
$4.1101
$21.00
Neonc Technologies Holdings Inc Stock (NTHI) Company Profile
NTHI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NTHI
Neonc Technologies Holdings Inc
|
4.36 | 112.29M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Neonc Technologies Holdings Inc 주식(NTHI)의 최신 뉴스
NeOnc Technologies Appoints New President Amid Strategic Moves - MSN
NeOnc Technologies announces global patent portfolio totals 176 - TipRanks
NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets - The Manila Times
NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical - Bluefield Daily Telegraph
NeOnc Sees Share Price Fall Since Going Public - Los Angeles Business Journal
NeOnc Technologies expects full enrollment in Phase 2a trial of NEO100-01 - TipRanks
NeOnc Technologies Expects Full Enrollment in Phase 2a Trialfor NEO100-01 by September - marketscreener.com
Neonc Technologies Holdings Expects Full Enrollment In Promising Phase 2A Trial Of Neo100-01 For Malignant Gliomas In September - MarketScreener
NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September - The Manila Times
Planet TV Studios Airing “New Frontiers” Episode on NeOnc Technologies Holdings, Inc. – Saturday, April 26th, - EIN News
New CEOs at Alterome, Valo and Imbria - BioCentury
NeOnc Technologies Appoints Executive Chairman Amir Heshmatpour as President - MarketScreener
NeOnc Technologies Holdings, Inc. Executive Chairman, Amir - GlobeNewswire
Germany's economy is expected to stagnate at best this year - The Globe and Mail
2 Reasons Nu Holdings Stock Is a Buy Before May 13 - The Globe and Mail
Rigetti Computing Stock (RGTI) Surges 21% as Market Optimism Returns - The Globe and Mail
NeOnc Technologies Phase 1 Trial Enrollment for NEO212 Brain Cancer Drug Nears Full Enrollment - MarketScreener
NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy - GlobeNewswire
Dow Jones Index Daily Report: DIA Rebounds Today After Tariff Tantrum - The Globe and Mail
Nvidia Stock (NVDA) Smashes Back as AI Demand Counters Tariff Panic - The Globe and Mail
NeOnc Technologies Partners with CBCC for Clinical Expansion - TipRanks
Neonc Technologies appoints new accounting firm By Investing.com - Investing.com Canada
Neonc Technologies appoints new accounting firm - Investing.com India
NeOnc Technologies receives RPDD for NEO100 - TipRanks
NeOnc Technologies Holdings: New IPO gets a Rare Pediatric Disease Designation and a 37.92% Jump in the Market - RagingBull
NeOnc Technologies Holdings' Perillyl Alcohol Receives FDA's Rare Pediatric Disease Designation - MarketScreener
NeOnc Falls Despite FDA Nod - Baystreet.ca
NeOnc Technologies Holdings, Inc. Receives Rare Pediatric - GlobeNewswire
Robinhood, Couchbase And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas - Yahoo Finance
NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments - The Manila Times
NeOnc Technologies Expands Global Clinical Trial Network - GlobeNewswire
NeOnc Technologies Holdings, Inc. Rings the Opening Bell - Nasdaq
NeOnc Technologies Holdings, Inc. Rings the Nasdaq Stock Market Opening Bell - Nasdaq
NTHI IPO NewsBiotech NeOnc Technologies' share registration declared effective ahead of Nasdaq direct listing - renaissancecapital.com
NeOnc Technologies Holdings Announces Effectiveness of - GlobeNewswire
NeOnc Technologies Holdings Announces Effectiveness of Registration Statement and Anticipated Listing Date of Common Stock on Nasdaq Global Market - Yahoo Finance
NEONC Technologies Holdings, Inc. Appoints Dr. Alan Chiang to its Board of Directors - Yahoo Finance
NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors - GlobeNewswire
NeOnc Technologies Holdings, Inc. Appoints Bader Almonawer to Board of Directors - GlobeNewswire
NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors - The Manila Times
NeOnc Technologies Holdings, Inc. Appoints Dr. Steven L. Giannotta to Board of Directors - Nasdaq
Nasdaq’s opening bell will ring for USC research startup NeOnc - USC Today
Q4 Gas and Liquid Handling Earnings: SPX Technologies (NYSE:SPXC) Impresses - The Globe and Mail
Planet TV Studios Airing “New Frontiers” Episode on NeOnc Technologies Holdings, Inc. – Saturday, March 15, - EIN News
Expanding horizons: NeOnc Technologies’ bold vision - The Business Journals
NeOnc Technologies plans to go public through direct listing - AlphaStreet
NeOnc Technologies has another go at a Nasdaq listing - Pharmaphorum
NeOnc Technologies Receives Pharma Tech Outlook’s Top Drug Delivery Platform Award for 2024 - GlobeNewswire
A Biotech Going Through the Nose to Treat the Brain Plots Alternative Path to Public Markets - MedCity News
NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate - GlobeNewswire
Neonc Technologies Holdings Inc (NTHI) 재무 분석
Neonc Technologies Holdings Inc (NTHI)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):